<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03584737</url>
  </required_header>
  <id_info>
    <org_study_id>1001</org_study_id>
    <nct_id>NCT03584737</nct_id>
  </id_info>
  <brief_title>Point-of-Care Immunoassay for Detection of Bacterial Sinusitis</brief_title>
  <official_title>Multi-Center Study of a Point-of-Care Immunoassay for the Detection of Bacterial Sinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ENTvantage Dx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beaufort</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Network Services (CNS) Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Entvantage Diagnostics Australia Pty Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ENTvantage Dx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to evaluate the performance of a rapid, point-of-care in vitro
      diagnostic device (Sinu-Test™) for the qualitative detection of the three most common
      pathogens responsible for causing bacterial sinusitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mucous specimens will be collected from patients displaying symptoms of acute bacterial
      sinusitis enrolled by primary care and/or otolaryngology clinics in the United States and
      Australia. Health care professionals not having endoscopy certification will collect
      specimens using the Entvantage sample collection device. Health care professionals with nasal
      endoscopy certification or specialty training will collect comparator specimens using an
      endoscope. Untrained operators with a range of education and training (primary care
      physician, otolaryngologist, physician assistant, nurse practitioner, registered nurse or
      other healthcare professional), will perform the Sinu-Test™ lateral flow assay in an
      outpatient setting. Mucous samples will be tested for the presence of 3 bacterial pathogens
      responsible for sinusitis using the Sinu-Test in the clinic and by the comparator method,
      standard quantitative bacterial culture with identification (matrix-assisted laser
      desorption/ionization-Time of Flight (MALDI-TOF) mass spectrometry instrument) by the central
      laboratory. Qualitative real-time polymerase chain reaction (real-time PCR) of the residual
      assay specimen will also be performed by the central laboratory.

      An additional cohort of individuals not displaying symptoms of acute bacterial sinusitis or
      illness will be included in the study to establish performance of the device with respect to
      colonizing bacteria.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 30, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of the diagnostic device</measure>
    <time_frame>One time subject sample result in 20-30 minutes for point-of-care test and 3-5 days for lab results</time_frame>
    <description>Assessment of the true positive and true negative rate of the point-of-care test device relative to the lab culture reference standard for each of the 3 bacterial microorganisms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value (PPV) and negative predictive value (NPV)</measure>
    <time_frame>One time subject sample result in 20-30 minutes for point-of-care test and 3-5 days for lab results</time_frame>
    <description>Positive predictive value is the probability that subjects with a positive point-of-care test truly have the bacteria present. Negative predictive value is the probability that subjects with a negative point-of-care test truly do not have the bacteria present.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Discordant results</measure>
    <time_frame>One time subject sample result in 20-30 minutes for point-of-care test and 3-5 days for lab results</time_frame>
    <description>Comparison of discordant results from point-of-care test device and lab culture with results from qualitative real-time PCR assay.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>Sinusitis Bacterial</condition>
  <arm_group>
    <arm_group_label>Symptomatic for bacterial sinusitis</arm_group_label>
    <description>Samples from participants showing symptoms of bacterial sinusitis tested by rapid in vitro diagnostic test, bacterial culture, and PCR assay</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy - no symptoms of sinusitis</arm_group_label>
    <description>Samples from healthy participants showing no symptoms of sinusitis tested by rapid in vitro diagnostic test, bacterial culture, and PCR assay</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>rapid in vitro diagnostic test</intervention_name>
    <description>IVD for qualitative detection of 3 bacterial pathogens (Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae)</description>
    <arm_group_label>Healthy - no symptoms of sinusitis</arm_group_label>
    <arm_group_label>Symptomatic for bacterial sinusitis</arm_group_label>
    <other_name>Sinu-Test™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>bacterial culture</intervention_name>
    <description>Quantitative bacterial culture assay with isolate identification by MALDI-TOF.</description>
    <arm_group_label>Healthy - no symptoms of sinusitis</arm_group_label>
    <arm_group_label>Symptomatic for bacterial sinusitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PCR assay</intervention_name>
    <description>Qualitative real-time PCR assay</description>
    <arm_group_label>Healthy - no symptoms of sinusitis</arm_group_label>
    <arm_group_label>Symptomatic for bacterial sinusitis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      nasal mucus in buffer solution
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at least 18 years of age with symptoms of bacterial sinusitis from primary care
        clinics and otolaryngology clinics.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets definition of acute sinusitis by Infectious Disease Society of America (2012)

        Exclusion Criteria:

          -  Chronic sinusitis

          -  Cystic fibrosis

          -  Patients treated with antibiotics currently or within the previous 30 days.

          -  Subjects with a prior history of sinus surgery will be excluded due to the
             modification of sinonasal anatomy.

          -  Primary immunodeficiencies, as self-reported

               -  Combined variable immunodeficiency

               -  Immunodeficiency with reduced immunoglobulin G (IgG) and immunoglobulin A
                  (IgA)-bearing cells

               -  Kartagener Syndrome (ciliary dyskinesia)

               -  Agammaglobulinemia

               -  Sickle cell disease

          -  Acquired immunodeficiencies, as self-reported

               -  Chemotherapy

               -  Radiation therapy

               -  Transplantation

               -  Asplenia

               -  HIV

               -  Poorly controlled Diabetes mellitus

          -  Cognitive impairment resulting in the inability to provide informed consent.

          -  Special groups, such as children under the age of 18, and men and women who are in
             prison will not participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jodi L Crutchleo, BS</last_name>
    <role>Study Director</role>
    <affiliation>Beaufort</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Achieve Clinical Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Empire Clinical Research</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Coast Ear, Nose &amp; Throat</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asclepes Research</name>
      <address>
        <city>Weeki Wachee</city>
        <state>Florida</state>
        <zip>34607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tandem Clinical Research</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENT and Allergy Associates</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimed Research</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARC Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillcrest Family Health Center</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paratus Clinical Kanwal Clinic</name>
      <address>
        <city>Kanwal</city>
        <state>New South Wales</state>
        <zip>2259</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paratus Clinical Kippa Ring Clinic</name>
      <address>
        <city>Kippa-Ring</city>
        <state>Queensland</state>
        <zip>4021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>June 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute sinusitis</keyword>
  <keyword>bacterial sinusitis</keyword>
  <keyword>point-of-care</keyword>
  <keyword>in vitro diagnostic device (IVD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

